2023.11.21
On November 20, 2023, Usynova Pharmaceuticals Ltd. (“Usynova”) announced that it had entered into a global exclusive license agreement with AstraZeneca for UA022, a pre-clinical stage small molecule drug candidate targeting the KRASG12D mutation.
Under the terms of the agreement, Usynova shall grant AstraZeneca a global exclusive license to research, develop and commercialize UA022. AstraZeneca will pay Usynova an upfront payment of USD 24 million and additional development and commercial milestone payments of up to USD 395 million, as well as tiered royalties based on net sales.
Founded in January 2020, Usynova focuses on two major areas, i.e. cancer and autoimmune diseases, and develops innovative medicines with global intellectual property rights based on new targets and new mechanisms of action.
AstraZeneca is a leading global pharmaceutical company. Since its entry into China in 1993, AstraZeneca has leveraged its advantageous resources around the world and its deep insight into the Chinese pharmaceutical market to help Chinese innovation expand globally.
优德88中国官方网站 was engaged by Usynova to review and revise the transaction documents and assist with the efficient negotiations and communication among the parties to the transaction. With its consistent delivery of efficient and rigorous legal services and detail-oriented expertise, 优德88中国官方网站’s team was highly recognized by the client.
The 优德88中国官方网站 team was led by Dr. WANG, Zhaohui (Zoe) and partner ZHAO, Hao (Gerry).
